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Abstract
Background: Between-center variation in outcome may offer opportunities to identify variation in quality of care.
By intervening on these quality differences, patient outcomes may be improved. However, whether observed
differences in outcome reflect the true quality improvement potential is not known for many diseases. Therefore,
we aimed to analyze the effect of differences in performance on structure and processes of care, and case-mix on
between-center differences in outcome after endovascular treatment (EVT) for ischemic stroke.
Methods: In this observational cohort study, ischemic stroke patients who received EVT between 2014 and 2017 in all 17
Dutch EVT-centers were included. Primary outcome was the modified Rankin Scale, ranging from 0 (no symptoms) to 6
(death), at 90 days. We used random effect proportional odds regression modelling, to analyze the effect of differences in
structure indicators (center volume and year of admission), process indicators (time to treatment and use of general
anesthesia) and case-mix, by tracking changes in tau2, which represents the amount of between-center variation in outcome.
Results: Three thousand two hundred seventy-nine patients were included. Performance on structure and process
indicators varied significantly between EVT-centers (P < 0.001). Predicted probability of good functional outcome
(modified Rankin Scale 0–2 at 90 days), which can be interpreted as an overall measure of a center’s case-mix, varied
significantly between 17 and 50% across centers. The amount of between-center variation (tau2) was estimated at 0.040
in a model only accounting for random variation. This estimate more than doubled after adding case-mix variables (tau2:
0.086) to the model, while a small amount of between-center variation was explained by variation in performance on
structure and process indicators (tau2: 0.081 and 0.089, respectively). This indicates that variation in case-mix affects the
differences in outcome to a much larger extent.
Conclusions: Between-center variation in outcome of ischemic stroke patients mostly reflects differences in case-mix,
rather than differences in structure or process of care. Since the latter two capture the real quality improvement potential,
these should be used as indicators for comparing center performance. Especially when a strong association exists
between those indicators and outcome, as is the case for time to treatment in ischemic stroke.
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Background
Endovascular treatment (EVT) has been shown to be a
highly effective treatment for patients with ischemic stroke
due to a proximal intracranial occlusion in the anterior cir-
culation [1–3]. EVT is defined as arterial catheterization
with a micro-catheter to the level of the occlusion, followed
by mechanical thrombectomy or thrombus aspiration, or
both, with or without delivery of a thrombolytic agent.
Currently EVT is widely implemented in routine clinical
practice, and the challenge is how to continuously improve
the quality of this service.
Worldwide, healthcare systems and practices are being
reorganized with a strong focus on measuring and improv-
ing outcomes of care. The quality of care for patients with a
specific medical condition is judged by the achieved out-
comes that are relevant for those patients. A central aspect
of this development is benchmarking, comparing quality of
care and specifically outcomes between healthcare pro-
viders, in this case EVT centers. If a specific center A has
better outcomes for a certain condition than center B, this
suggests that center B should copy the medical management
strategy of center A in order to improve the quality of care
in that center. An important problem of this approach,
however, is the variability in baseline characteristics of pa-
tients (‘case-mix’) that often exists between centers. If center
B treats more severely affected patients than center A, this
might (partly) explain the better outcomes of center A.
Moreover, especially if centers are relatively small, between-
center differences in outcome may be caused by chance
(‘random variation’). Therefore, between-center compari-
sons of outcome should be adjusted for case-mix and ran-
dom variation. If not done properly, such comparisons are
likely to miss their purpose and could even be counterpro-
ductive as clinicians may base their decisions on flawed in-
formation. Furthermore, following Donabedian’s framework
for evaluating healthcare quality, the quality improvement
potential is especially captured by variation in structures
(‘How is care organized?’) and processes (‘What is done?’) of
care [4]. For many diseases, however, it is unknown whether
between-center variation in outcome reflects true differ-
ences in quality of care, captured by this framework.
Using data from a large nation-wide registry, the aim
of this study was to assess the effect of structure and
process indicators on between-center variation in out-
come for ischemic stroke patient treated with EVT,
while adjusting for case-mix and random variation.
Methods
Study design and patients
For this study we used data collected between March 2014
and November 2017 from the MR CLEAN Registry, a pro-
spective, observational study in all 17 centers that perform
EVT in the Netherlands (Supplementary Figure 1) [5]. This
registry is unique since it includes clinical and neuro-
imaging data of all patients treated with EVT in one coun-
try during a multi-year period and thereby reflects clinical
practice. All patients undergoing EVT for acute ischemic
stroke have been registered. Inclusion criteria were: age 18
years and older, treatment in a center that participated in
the MR CLEAN trial, and proximal intracranial vessel
occlusion in the anterior circulation (internal carotid artery
(ICA), internal carotid artery terminus (ICA-T), middle
(M1/M2) cerebral artery, or anterior (A1/A2) cerebral
artery), as shown by computed tomography angiography
(CTA). Details on the study design and objectives of the
MR CLEAN Registry have been described elsewhere [5].
Overall, data from 3279 patients were included for the
current analysis (Supplementary Figure 2).
The MR CLEAN Registry was approved by the ethics
committee of the Erasmus University MC, Rotterdam,
The Netherlands (MEC-2014-235). With this approval it
was approved by the research board of each participating
center. At UMC Utrecht, approval to participate in the
study has been obtained from their own research board
and ethics committee.
Case-mix indicators
For case-mix adjustment we used the following patient and
neuro-imaging characteristics: age, sex, relevant medical
history (i.e. previous stroke, atrial fibrillation, myocardial
infarction, peripheral arterial disease, hypertension, diabetes
mellitus, hypercholesterolemia), pre-stroke score on the
modified Rankin Scale (mRS), the baseline score on the Na-
tional Institute of Health Stroke Scale (NIHSS) as a stroke-
related neurologic deficit score, and occlusion location and
collateral grade on CT angiography. These characteristics
were selected based on clinical knowledge and previous
studies [6, 7]. Two additional characteristics were consid-
ered as case-mix indicators, because these are strongly
associated with outcome but not influenceable by the
centers: time between stroke onset and arrival at the emer-
gency department (ED) of the intervention center, and
whether or not the patient had been admitted to another
center before being transferred to the intervention center
[8, 9]. Stroke onset was defined as the time point when the
sudden appearance of stroke symptoms was witnessed by
the patient or an observer. In cases the time of first symp-
toms was unknown, onset was defined as the moment the
patient was last seen well.
Quality of care indicators
Quality of care indicators were defined using Donabe-
dian’s framework comprising indicators of structure,
process, and outcome [4]. Both center volume and year
of admission reflect the experience of a center with EVT
and were used as structure indicators. Center volume
was defined as the percentage of all EVT-patients treated
in each center relative to all EVT-patients treated in the
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Netherlands in the study period. In stroke care, high
center volume was found to be associated with lower
stroke-related mortality [10]. In other studies, higher
volume stroke centers showed better outcomes on aver-
age [11–13]. Since EVT is a relatively new treatment in
stroke care, we hypothesized (overall) performance to in-
crease with calendar year and therefore added year of
admission as an additional structure indicator.
Two process indicators were defined: time from arrival at
the emergency department of the intervention center to
groin puncture and the use of general anesthesia (yes/no). A
significant negative association between ‘time-to-groin’ and
outcome was found in previously published research, indi-
cating that time delays before initiation of EVT have a nega-
tive effect on the likelihood of independent functional
recovery at 90 days [8, 13–17]. So far, no differences in out-
comes between general anesthesia and conscious sedation
were observed in previous randomized controlled trials
[18–20]. In several meta-analyses of observational studies,
conscious sedation was associated with better outcomes
than general anesthesia [21–23]. Although general
anesthesia reduces the risk of patient agitation, unnecessary
use of general anesthesia increases time delay in the total
process of care, intra-procedural complications, and may
result in cerebral hypoperfusion (e.g. through fluctuations in
blood pressure on general anesthesia induction and abnor-
mal cerebral auto-regulation) [24, 25]. Overall, we expected
the use of general anesthesia to influence patient outcome,
and therefore defined this as an additional process indicator.
We used the modified Rankin Scale (mRS) score as
the outcome indicator [26]. The mRS score is a com-
monly used measure of patients’ functional outcome
after ischemic stroke, and ranges from 0 (no symptoms)
to 6 (death). The mRS score was assessed at 90 days after
EVT (± 14 days). Good functional outcome, defined as
mRS 0–2, was used as secondary outcome (see below).
Statistical analyses
Descriptive analyses
We used Pearson’s chi-square statistic and the non-
parametric Kruskal Wallis test for a univariable compari-
son of centers on case-mix and quality of care indicators.
The predicted probability of good functional outcome can
be considered an overall measure of each centers’ case-
mix. To calculate this, we first fitted an individual-level lo-
gistic regression model including all case-mix indicators
as predictors and yes/no good functional outcome (mRS
0–2 at 90 days) as the dependent variable. The predicted
patient-level probabilities by this model were then used to
calculate the median predicted probability per center.
Random effect regression models
In order to adjust for random variation and assess the effects
of adjusting for case-mix and performance on structure and
process indicators on between-center variation in outcome,
we used random effect proportional odds regression model-
ling. A random center effect (intercept) accounts for the fact
that the observed outcomes for lower-volume centers can
take extreme values due to random variation. A proportional
odds model exploits the full ordinal nature of the mRS as an
outcome scale with more than two possible categories [27].
In all analyses, we used the inverse of the mRS score for
each patient. Doing so allows us to interpret the estimates
as the effects on the likelihood of a more favorable out-
come, since a higher score on the inverse of the mRS
means more favorable outcome (see above). We estimated
common odds ratios with 95% confidence intervals on the
patient level using four proportional odds regression
models [27]. First, we fitted an ‘empty’, unadjusted model
including only a random center effect, providing insight in
between-center variation in outcome accounting only for
random variation. In the second model, in addition to the
random center effect, we adjusted for the individual-level
fixed effects of case-mix indicators on outcome. In the third
model, we added the fixed effects of the structure indicators
to the model. Finally, the fourth model also contains the
individual-level fixed effects of the process indicators.
Between-center variation
To assess the relative impact of adjusting for case-mix
and performance on structure and process indicators on
between-center variation in outcome, we compared the
variance of the random center effect (tau2) across
models. Essentially, tau2 reflects the amount of between-
center variation in outcome. In addition, separately for
each model, we constructed forest plots to visualize this
variation using estimates of center-specific outcome (i.e.
the random center effects). The predictive power of the
four models was compared using Akaike’s Information
Criterion (AIC), in which a lower AIC value indicates a
higher predictive power for outcome [28].
Missing data
Multiple imputation was used to deal with missing data,
which ranged between 0.7% (previous diabetes) to 6.3%
(collateral grade) [5]. We fitted regression imputation
models [29, 30] and imputed data five times, using the
following variables: age, sex, medical history, pre-stroke
mRS score, location of occlusion, collateral grade, base-
line NIHSS score, whether patient transferred from
other hospital, time intervals from onset to arrival at the
ED, center volume per year, year of admission, time in-
tervals from onset to groin puncture, and use of general
anesthesia. Each imputed dataset was analyzed separ-
ately, after which the results were pooled.
All statistical analyses were performed with R statis-
tical software version 3.4.3 (R Foundation for Statistical
Computation, Vienna, Austria), using the clmm module
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in the ordinalimputation package. Statistical significance
was assessed at P < 0.05 in all analyses.
Results
Descriptive analyses
At the center level, the median patient age ranged from 68
to 77 years, with statistically significant differences between
centers (Table 1). Differences between centers were also
statistically significant for previous stroke (range 0–26%),
atrial fibrillation (13–37%), peripheral arterial disease (4–
22%), hypertension (41–67%), hypercholesterolemia (15–
50%), pre-stroke mRS, location of occlusion, collateral
grade, baseline NIHSS score (range median score per center
13–17) and percentage of transferred patients from another
hospital (0–77%). Median time of stroke onset to arrival at
the ED of the intervention center ranged from 52 to 160
min across centers (P < 0.001). Importantly, the median
predicted probability of good functional outcome (mRS 0–
2 at 90 days), which can be interpreted as an overall meas-
ure of a center’s case-mix, varied between 17 and 50%
across centers (P = 0.004) (Table 1 and Supplementary
Table 1). The patient-level effect estimates of case-mix
variables on outcome shown in Supplementary Figure 3 are
comparable to the results of prior research [31].
Relative to the total number of patients in our data, the
number of EVT-patients varied significantly between cen-
ters across the 4 years (Fig. 1). Median time from arrival at
the ED of the intervention center to groin puncture also
varied substantially: between 74 and 125min for non-
transferred patients (P < 0.001) and between 20 and 60min
for transferred patients (P < 0.001). Variation in the use of
general anesthesia (0–99%) was also statistically significant.
Crude differences in outcome were statistically significant
(P < 0.001) across centers for mRS values 0–6: no symp-
toms (1–18%), no significant disability (7–26%), slight dis-
ability (4–29%), moderate disability (4–20%), moderately
severe disability (7–31%), severe disability (2–11%), and
death (21–36%) (Table 2 and Supplementary Table 2).
Predictive power for outcome
Model 1 generated an AIC of 11,158, which dropped to
10,050 after adding case-mix variables in model 2, sug-
gesting a considerably improved predictive power
(Table 3). Adding structure (AIC = 10,043) and process
indicators (AIC = 10,012) only slightly improved the pre-
dicted power further (Table 3).
Between-center variation in outcome
In model 1, which only adjusts for random variation, the
amount of the between-center variation in outcome (tau2)
was 0.040 (Table 3). The tau2 represents the amount of
variability in outcome between centers. This estimate more
than doubled after adding case-mix indicators (model 2,
tau2: 0.086), while adding structure indicators (model 3)
and process indicators (model 4) left it almost unaffected
(tau2: 0.081 and 0.089, respectively). This indicates that
only a small amount of between-center variation was ex-
plained by variation in performance on structure and
process indicators. This finding is also reflected in the forest
plots (Fig. 2), which for each model show the estimated ef-
fects of all 17 centers on the likelihood of favorable out-
come. Between-center variation increased particularly after
case-mix indicators were added (compare Fig. 2b with Fig.
2a), while variation remained rather constant after adding
structure (Fig. 2c) and process (Fig. 2d) indicators.
Discussion
This study focused on assessing variation in outcome be-
tween centers treating ischemic stroke with EVT in the
Netherlands, and the impact of differences in case-mix
and in performance on structure and process indicators.
Our results show that differences in case-mix have a
much larger impact on between-center differences in
outcome for stroke patients treated with EVT than dif-
ferences in structure and processes of care across cen-
ters. Therefore, an (unadjusted) measure of functional
outcome may not be a valid indicator for quality of care
when comparing stroke centers.
Outcome indicators as measures of quality of care
Benchmarking initiatives increasingly use outcome mea-
sures to compare quality of care between centers. However,
as found in this study, significant differences in perform-
ance on evidence- and consensus-based measures of (pro-
cesses of) care may not be reflected in between-center
differences in outcome. An important explanation for this
is the observational nature of the data that are typically
used in such benchmarking initiatives. When assessing the
effect of interventions or processes of care on outcome in
such data, confounding by indication is a major issue. For
example, physicians might treat more severely affected
patients faster than less severely affected patients [32, 33].
As disease severity is likely to influence outcome, in obser-
vational data it can confound the estimated relation with
outcome insofar severity is insufficiently accounted for. Al-
though we adjusted for disease severity in several ways
using measured case-mix variables, we cannot preclude the
possibility that our estimated effect of time to treatment on
outcome is to some extent biased. This could partly be be-
cause of a residual unmeasured case-mix effect, as well as
unaccounted for technical parameters. Knowing the associ-
ation of center-level outcomes with process indicators and
structural characteristics allows decision-makers to under-
stand the determinants of performance and implement im-
provement strategies; in other words, all indicators should
be retained to get an empirical (i.e., context specific) evalu-
ation of the quality of care. If a center is an “outlying
provider” even after accounting for patient case mix and
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process/structural characteristics, in-depth analyses and
audit activities should be put in place to understand the
reasons for this center’s outlying performance. Given that
detecting a beneficial effect of effective interventions on
outcome can be difficult even in large methodologically
sound randomized trials, observing effects of evidence- and
consensus-based indicators of (processes of) care on
between-center differences in outcome may be even harder
in benchmarking initiatives using observational registry
data. In other words, when observational data are used for
benchmarking, which in practice is typically the case, good
performance on structure and process indicators may not
be reflected in favorable outcome due to unmeasured con-
founding factors. Therefore, identifying and benchmarking
performance on indicators with a proven contribution to
favorable outcomes should be an important future direc-
tion for stroke care quality assessment and improvement
initiatives.
Table 1 Case-mix characteristics of patients treated in intervention centers in MR CLEAN Registry











Age (years) 72 (61–80) 68–77 3279 0 0.001
Men 1696 (52) 39–55 3279 0 0.790
Medical History
Previous Stroke 546 (17) 0–26 3252 27 (0.8) < 0.001
Atrial Fibrillation 772 (24) 13–37 3236 43 (1.3) < 0.001
Myocardial Infarction 453 (14) 4–18 3212 67 (2.0) 0.16
Peripheral Arterial Disease 301 (9) 4–22 3211 68 (2.1) < 0.001
Hypertension 1688 (53) 41–67 3213 66 (2.0) < 0.001
Diabetes 532 (16) 12–25 3255 24 (0.7) 0.09
Hypercholesterolemia 967 (31) 15–50 3136 143 (4.4) < 0.001
Pre-stroke modified Rankin Scale score 3207 72 (2.2) < 0.001
0 2170 (68) 45–87
1 424 (13) 3–19
2 241 (8) 0–16
≥ 3 372 (12) 5–25
Location of occlusion 3119 160 (4.99) < 0.001
M1 1815 (58) 45–70
M2 455 (15) 4–31
Intracranial ICA 161 (5) 0–10
ICA-T 663 (21) 9–27
Other (M3/anterior) 25 (1) 0–4
Collateral grade 3072 207 (6.3) < 0.001
0 (Absent) 187 (6) 0–9
1 (< 50%) 1100 (36) 17–46
2 (> 50% but < 100%) 1190 (39) 33–61
3 (100%) 595 (19) 10–37
Baseline NIHSS score 16 (11–20) 13–17 3224 55 (1.7) < 0.001
Transferred patients from other hospital 1783 (54) 0–77 3279 0 < 0.001
Time from onset to arrival at the ED (min) 135 (65–195) 52–160 3155 124 (3.8) < 0.001
Predicted probability of good functional outcomea 41 (20–62) 17–50 2550 729 (22.2) 0.004
IQR Interquartile range, ICA-T internal carotid artery terminus, M1/M2 middle cerebral artery, NIHSS National Institutes of Health Stroke Scale, ED Emergency department
aPredicted probability (%) of good functional outcome (modified Rankin Scale score 0–2 at 90 days) is based on an individual-level logistic regression model
predicting good functional outcome from the case-mix variables included in this table. See Supplementary Table 1 for details of case-mix characteristics of
patients treated in each intervention center
*P-value is based on comparison between 17 centers using a non-parametric Kruskal Wallis test for continuous variables or Pearson’s chi-square statistic for
categorical variables
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Fig. 1 Center volume in each intervention year. Center volume is defined as percentage of all EVT patients treated in each center relative to all
EVT patients treated in the Netherlands in that year
Table 2 Quality of care indicators of all 17 intervention centers in the Netherlands












Center volume 3279 0
2014 187 (6a) 0–18 < 0.001
2015 822 (25) 1–13 < 0.001
2016 1131 (34) 1–14 < 0.001
2017 1139 (35) 0.3–13 < 0.001
Processes
Time from arrival at the ED to groin puncture in non-transferred
patients (min)
90 (70–119) 74–125 1292 203 (6.2) < 0.001
Time from arrival at the ED to groin puncture in transferred
patients (min)
39 (26–57) 20–60 1722 61 (1.9) < 0.001
Use of general anesthesia 778 (25) 0–99 3082 197 (6.0) < 0.001
Outcome
Modified Rankin Scale (mRS) score at 90 days 3065 214 (6.5) < 0.001
mRS 0 (No symptoms) 209 (7) 1–18
mRS 1 (No significant disability) 471 (15) 7–26
mRS 2 (Slight disability) 561 (18) 4–29
mRS 3 (Moderate disability) 404 (13) 4–20
mRS 4 (Moderately severe disability) 366 (12) 7–31
mRS 5 (Severe disability) 168 (6) 2–11
mRS 6 (Dead) 886 (29) 21–36
IQR Interquartile range, ED Emergency department, EVT endovascular treatment
aPercentage of all EVT patients treated in the Netherlands in that year (see Fig. 1 for details)
*P-value is based on comparison between 17 centers using a non-parametric Kruskal Wallis test for continuous variables or Pearson’s chi-square statistic for
categorical variables
See Supplementary Table 1 for details of quality of care indicators in each intervention center
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Between-center differences in outcome after case-mix
adjustment
The observed difference of the unadjusted and adjusted es-
timated center effect is because of statistical consideration
and is a result of both imbalance and stratification [34, 35].
Good outcomes will generally be more difficult to achieve
for patients who are more severely affected at baseline.
Therefore, the observed outcomes of centers with a rela-
tively ‘severe’ case-mix will on average be less favorable (i.e.
biased downwards) as compared to those of centers with a
Table 3 Results from the random effect proportional odds regression analysis using the inverse of the modified Rankin Scale at 90
days as the dependent variable
Model 1 Model 2 Model 3 Model 4
Center volume [OR (95% CI)] – – 1.01 (0.98–1.04) 1.01 (0.98–1.05)
Year of admission [OR (95% CI)] – –
2014 ref ref
2015 1.32 (0.95–1.85) 1.20 (0.86–1.67)
2016 1.67 (1.22–2.28) 1.36 (0.98–1.90)
2017 1.60 (1.17–2.19) 1.27 (0.91–1.77)
Time from arrival at the ED of intervention center
to groin puncture (every 30 min) [OR (95% CI)]
– – – 0.87 (0.82–0.92)
Use of general anesthesia [OR (95% CI)] – – – 0.72 (0.57–0.90)
Variance of random center intercept [tau2(95% CI)]# 0.040 (0.012–0.113) 0.086 (0.042–0.261) 0.081 (0.028–0.227) 0.089 (0.033–0.254)
AIC 11,158 10,050 10,043 10,012
ED Emergency department, AIC Akaike’s Information Criterion. A lower AIC value indicates a better model fit
Model 1 (‘unadjusted model’) includes a random center intercept only
Model 2 (‘case-mix adjusted model’) includes a random center intercept and the case-mix indicators (Table 1). See Supplementary Figure 3 for the estimated fixed
effects of each case-mix indicator
Model 3 (‘case-mix and structure indicators adjusted model’) includes a random center intercept, case-mix indicators, and structure indicators
Model 4 (‘case-mix, structure and process indicators adjusted model’) includes a random center intercept, case-mix indicators, structure indicators, and
process indicators
#95% CIs around τau2 were estimated using single imputed data with bootstrap
Fig. 2 Forest plots reporting random center effect (odds ratios and 95% confidence intervals) on inverse of modified Rankin Scale at 90 days in
four models using random effect proportional odds regression analysis. a: Model 1 (unadjusted model); b: Model 2 (case-mix adjusted model); c:
Model 3 (case-mix and structure indicators adjusted model); d: Model 4 (case-mix, structure and process indicators adjusted model)
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relatively ‘mild’ case-mix (i.e. biased upwards). In general,
adjusting for the imbalance in case-mix would then reduce
observed variation in outcome between centers. However,
in this study an opposite pattern is observed. After adjust-
ing for case-mix, actual between-center differences in out-
come become visible. Apparently, centers with a more
severe case-mix tend to have relatively good outcomes and
vice versa. Although counterintuitive, this still underlines
the necessity of appropriate case-mix adjustment in bench-
marking quality performance using observational data. Be-
sides the effect of adjusting for the imbalance, more
extreme center effect after adjustment could be a result of
the stratification effect. Although “stratification” usually re-
fers to conditioning on categoric subgroups (e.g. on sex),
we also use this term when continuous variables are in-
volved, for example, age. Adjustment will generally increase
standard errors, and the stratification (adjustment) effect
will lead to more extreme effect estimates [34].
Strengths and limitations
In previous studies [6, 7], a dichotomized version of the
mRS was used (mRS ≥3 was considered as ‘poor outcome’)
and analyzed using binary logistic regression models. In
order to exploit the full ordinal nature of the mRS score,
we used proportional odds regression analysis. In addition,
the use of random effect analyses allowed us to estimate
(the variance of) center outcomes adjusted for random
variation and various other factors (i.e. case-mix, struc-
ture, and process indicators).
A first limitation of this study is the unavailability of
other potentially contributing factors to between-center
outcome differences, e.g. unmeasured patient characteris-
tics, care processes, and center characteristics. A second
limitation is that missing values may have introduced some
bias, although we believe to have mitigated this issue con-
siderably using multiple imputation, which is the preferred
method over complete case analysis [36, 37]. A third limi-
tation is low number of second-level units, with resulting
lack of precision in tau2 estimates. A final limitation is that
we only analyzed one outcome. Although the mRS is used
as an outcome in virtually all modern stroke trials, our
conclusions might have been different if we had used other
outcomes that are relevant to stroke patients treated with
EVT, like patient-reported outcomes such as quality of life.
In addition, even though the mRS is an appropriate tool
for assessing patient disability after stroke care, it may not
be easily transferrable to outcomes research. After all, in
many countries other than the Netherlands, the mRS is
not routinely collected for all acute stroke patients. How-
ever, if we would have used clinical outcomes that are
commonly registered in administrative databases, such as
short-term mortality or readmission, we would have less
certainty about our estimations because of the much
smaller number of events in the context of acute stroke
treatment. Moreover, from a clinical perspective these
outcome measures are far less relevant in the stroke
context compared to the mRS. Therefore, we used the
mRS as the most powerful and clinically relevant out-
come for our study.
Conclusions
In this study, we have demonstrated that between-center
differences in performance on structure and process
indicators have a small impact on functional outcome of
ischemic stroke patients treated with EVT, while differ-
ences in case-mix affects this variation substantially.
Thus, outcome indicators may not be valid and useful
for comparing and improving the quality of stroke care
based on observational data. Since variation in perform-
ance on structure and process indicators captures real
quality improvement potential, these indicators should
be used in future benchmarking initiatives. This is espe-
cially true when a strong association exists between
those indicators and outcome, as is the case for time to
treatment in ischemic stroke.
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